KLOR-CON

Post-LOE

potassium chloride

Ascentage Pharma

ANDAORALFOR SOLUTION

Approved

Oct 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

KLOR-CON (potassium chloride) by Ascentage Pharma is (k ) is the principal intracellular cation of most body tissues. Approved for without metabolic alkalosis, digitalis intoxication, hypokalemia in patients. First approved in 2017.

Drug data last refreshed Yesterday

$0.0BPart D

Mechanism of Action

(K ) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the…

Indications (3)

without metabolic alkalosis digitalis intoxication

Worked on KLOR-CON at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.